541 related articles for article (PubMed ID: 24462284)
21. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.
Govaerts K; Chandrakumaran K; Carr NJ; Cecil TD; Dayal S; Mohamed F; Thrower A; Moran BJ
Eur J Surg Oncol; 2018 Sep; 44(9):1371-1377. PubMed ID: 30017331
[TBL] [Abstract][Full Text] [Related]
22. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
[TBL] [Abstract][Full Text] [Related]
23. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
24. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
Alexander-Sefre F; Chandrakumaran K; Banerjee S; Sexton R; Thomas JM; Moran B
Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
[TBL] [Abstract][Full Text] [Related]
25. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Sugarbaker PH
Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Iversen LH; Rasmussen PC; Hagemann-Madsen R; Laurberg S
Colorectal Dis; 2013 Jul; 15(7):e365-72. PubMed ID: 23458368
[TBL] [Abstract][Full Text] [Related]
27. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
Järvinen P; Ristimäki A; Kantonen J; Lepistö A
Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
[TBL] [Abstract][Full Text] [Related]
29. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
[TBL] [Abstract][Full Text] [Related]
30. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Klaver YL; Chua TC; Verwaal VJ; de Hingh IH; Morris DL
J Surg Oncol; 2013 May; 107(6):585-90. PubMed ID: 23280508
[TBL] [Abstract][Full Text] [Related]
31. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
33. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
[TBL] [Abstract][Full Text] [Related]
34. Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.
Riss S; Chandrakumaran K; Dayal S; Cecil TD; Mohamed F; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):392-5. PubMed ID: 25238953
[TBL] [Abstract][Full Text] [Related]
35. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
36. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
[TBL] [Abstract][Full Text] [Related]
38. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
[TBL] [Abstract][Full Text] [Related]
39. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
[TBL] [Abstract][Full Text] [Related]
40. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
